



# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Givlaari Clinical Edit
<b>First Implementation Date:</b>	July 30, 2020
<b>Revised Date:</b>	August 4, 2022
<b>Prepared for:</b>	MO HealthNet
<b>Prepared by:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** Ensure appropriate utilization and control of Givlaari® (givosiran)

**Why Issue Selected:** Givlaari® (givosiran) was approved by the FDA in November 2019, for the treatment of acute hepatic porphyria (AHP) in adults. Porphyria refers to a group of at least 8 inherited metabolic disorders that arise as a result of a malfunction in the synthesis of heme, which is essential for the transport of oxygen to cells in the body. AHP is comprised of four types of porphyrias: acute intermittent porphyria, hereditary coproporphyria, variegate porphyria and ALA dehydratase-deficiency porphyria. Symptoms of AHP vary widely but typically occur as intermittent attacks, which may be life-threatening due to neurologic complications such as seizures or paralysis. Approximately 20% of patients with recurrent symptoms develop chronic and ongoing pain and other symptoms, and approximately 3-5% of patients have frequent attacks, defined as more than 4 attacks per year, for a period of many years. Long-term complications of AHP include hypertension, chronic kidney disease, and liver disease (including hepatocellular carcinoma). Givlaari is a double-stranded small interfering RNA that causes degradation of aminolevulinic acid synthase 1 (ALAS1) mRNA in hepatocytes through RNA interference, reducing the elevated levels of liver ALAS1 mRNA. This leads to reduced circulating levels of neurotoxic intermediates aminolevulinic acid (ALA) and porphobilinogen (PBG), factors associated with attacks and other disease manifestations of AHP.

Due to the high cost and specific approved indication, MO HealthNet will impose clinical criteria to ensure appropriate utilization of Givlaari.

Program-Specific Information:	Date Range FFS 1-1-2021 to 12-31-2021			
	Drug	Claims	Spend	Avg Spend Per Claim
	GIVLAARI 189 MG/ML VIAL	5	\$234,044.25	\$46,808.85

**Type of Criteria:**  Increased risk of ADE  Preferred Drug List  
 Appropriate Indications  Clinical Edit

**Data Sources:**  Only Administrative Databases  Databases + Prescriber-Supplied

*SmartPA Clinical Proposal Form*  
 © 2022 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

## Setting & Population

- Drug class for review: Givlaari® (givosiran)
- Age range: All appropriate MO HealthNet participants aged 18 years or older

## Approval Criteria

- Participant aged 18 years or older **AND**
- Prescribed by or in consultation with a hepatologist, gastroenterologist, or other specialist in the treated disease state **AND**
- Documented diagnosis of acute hepatic porphyria (AHP) **AND**
- Documentation of labs used to verify AHP diagnosis (spot or 24 hour urine delta-aminolevulinic acid (ALA), porphobilinogen (PBG), and creatinine with results 4 times ULN) **AND**
- Documentation of active disease defined as at least 1 porphyria attack within the past 6 months (defined by hospitalization, urgent healthcare visit, or intravenous hemin therapy) **AND**
- Documentation of current LFTs, serum creatinine, **and blood homocysteine levels**
- Renewal Criteria:
  - Initial approval of prior authorization is 6 months
  - Renewal of prior authorization may be up to 12 months following documentation of the following:
    - Documentation of stabilized or decreased AHP attack frequency (i.e. decreased hospitalizations, urgent healthcare visits, or hemin therapy) **AND**
    - Documentation of current LFTs < 3 times the ULN (monthly during the first 6 months of therapy and then at least once annually) **AND**
    - Documentation of current serum creatinine (at least once annually) **AND**
    - **Documentation of current blood homocysteine levels (at least once annually)**

## Denial Criteria

- Therapy will be denied if all approval criteria are not met

## Required Documentation

Laboratory Results:  
MedWatch Form:

X

Progress Notes:  
Other:

X
X

## Disposition of Edit

Denial: Exception code "0682" (Clinical Edit)  
Rule Type: CE

## Default Approval Period

6 months

## References

- GIVLAARI® (givosiran) injection, [package insert]. Cambridge, MA: Alnylam Pharmaceuticals, Inc.; October 2021.
- American Porphyria Foundation. <https://www.porphyrifoundation.org/>. Accessed February 2, 2022.

*SmartPA Clinical Proposal Form*  
© 2022 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

- National Organization for Rare Disease. Porphyria. <https://rarediseases.org/rare-diseases/porphyria/>. Accessed February 2, 2022.
- Wang, B, et al. Acute Hepatic Porphyrias: Review and Recent Progress. *Hepatology Communications*, Vol 3, Issue 2. December 20, 2018. <https://doi.org/10.1002/hep4.1297>
- IPD Analytics. Hematologic: Porphyria. Accessed February 2, 2022.
- IPD Analytics. New Drug Review: Givlaari (givosiran). December 2019.
- Rosenson R, Smith C, Bauer K. Overview of homocysteine. UpToDate. [Overview of homocysteine - UpToDate](#). Accessed February 2, 2022.
- Yarra, Pradeep & Faust, Denise & Bennett, Mary & Rudnick, Sean & Bonkovsky, Herbert. (2019). Benefits of prophylactic heme therapy in severe acute intermittent porphyria. *Molecular genetics and metabolism reports*. 19. 100450. 10.1016/j.ymgmr.2019.01.002.